Transcription factor RNA interference reagents and methods of use thereof

A method of treating, ameliorating, or preventing a disorder comprising the step of administering to a cell, tissue, and/or subject, a pharmaceutically effective amount of an RNAi reagent selected from the group consisting of:

• SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, and SEQ ID NO:27;
• wherein said cell, tissue, and/or subject is mammalian and/or human.

A method of treating restenosis in a host, wherein said method comprises the step of introducing an RNAi reagent selected from the group consisting of:

• SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12;
• into vascular smooth muscle cells at the site of a vascular lesion, wherein said cells are capable of resulting in restenosis as a result of neointima formation, in an effect amount to inhibit said neointima formation.

A method of inhibiting proliferative lesion formation in a blood vessel, said method comprising the step of introducing into vascular smooth muscle cells of said blood vessel an RNAi reagent selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ iID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, and SEQ ID NO:27;

• in an amount sufficient to inhibit proliferative lesion formation in said blood vessel.

A method of identifying a compound that modulates the biological activity of the E2F1 polypeptide, or a biological pathway of said polypeptide member, or a downstream effector of said polypeptide member;

• comprising the steps of, (a) combining a candidate modulator compound with said polypeptide member in the presence of a nucleic acid that antagonizes the expression and/or activity of said polypeptide member wherein said nucleic acid is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, and SEQ ID NO:27, and (b) identifying candidate compounds that reverse the antagonizing effect of said nucleic acid member.